Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Carcinoma, Renal Cell 11Sarcoma 6Neoplasms 6Lymphoma, Mantle-Cell 6Prostatic Neoplasms 5Lymphoma, Non-Hodgkin 5Rhabdomyosarcoma 4Neoplasm Metastasis 4Kidney Neoplasms 4Gliosarcoma 4Glioblastoma 4Breast Neoplasms 4Brain Neoplasms 4Waldenstrom Macroglobulinemia 3Osteosarcoma 3Melanoma 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Endometrial Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Oligodendroglioma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Liposarcoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Glioma 2Fallopian Tube Neoplasms 2Carcinoma, Hepatocellular 2

Interventions

temsirolimus 1Sorafenib 1Sirolimus 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Recurrent Uterine Sarcoma × temsirolimus × Clear all
NCT01061606 2016-11-09

Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus

National Cancer Institute (NCI)

Phase 2 Terminated
8 enrolled 6 charts
GynecologicSarcoma

Recurrent Uterine Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡